Chemomab Therapeutics Ltd.
Cash Flow Statement
| Line Item | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-1.7M | $-2.0M | $-1.2M | $-1.1M | $-1.7M | $-5.6M | $-7.2M | $-4.4M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $7.0K | $6.0K | $8.0K | $5.0K | $5.0K | $211.0K | $28.0K | $21.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $43.0K | $33.0K | $23.0K | $28.0K | $46.0K | $89.0K | $321.0K | $368.0K |
| Net Cash from Operating Activities | $-1.3M | $-1.6M | $-901.0K | $-873.0K | $-1.9M | $-5.9M | $-3.5M | $-3.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $3.0K | $1.0K | $20.0K | $7.0K | $10.0K | $-251.0K | $255.0K | $16.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-2.0K | $-3.0K | $-20.0K | $-29.0K | $-10.0K | $251.0K | $-255.0K | $-16.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $47.8M | $563.0K | $562.0K | $3.1M | $500.0K | $0 | $0 | $-1.2M |
| Net Change in Cash | $46.5M | $-995.0K | $-359.0K | $2.2M | $-1.4M | $-5.7M | $-3.8M | $-5.1M |
| Free Cash Flow | $-1.3M | $-1.6M | $-921.0K | $-880.0K | $-1.9M | $-5.7M | $-3.8M | $-3.9M |